Faculty Perspectives: Advances in the Treatment of Hematologic Malignancies: Updates from ASH 2013

Continuing Education

Estimated time to complete activity: 1 hour

Date of initial release: February 18, 2014

Valid for CPE/CME/CE credit through: February 18, 2015

Target Audience
This educational program is designed for medical oncologists, hematologists, oncology nurses, advanced practice nurses, oncology/hematology nurse practitioners, physician assistants, and oncology/hematology pharmacists who participate in the management of patients with hematologic malignancies.

Learning Objectives
Upon completion of this activity, the participant will be able to:
  • Discuss emerging data and recent advances in the personalized treatment of patients with hematologic malignancies, and integrate key findings into clinical practice
  • Outline contemporary prognostic and predictive biomarkers and patient characteristics for MM, CLL, NHL, HL, MDS, and MF and apply the results to create an individualized approach to managing each patient
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology